Immunogen Inc (DELISTED) (IMGN:DL)
31.23
0.00 (0.00%)
USD |
NASDAQ |
Feb 13, 16:00
Immunogen Revenue (Quarterly): 113.42M for Sept. 30, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 113.42M |
| June 30, 2023 | 83.15M |
| March 31, 2023 | 49.87M |
| December 31, 2022 | 41.17M |
| September 30, 2022 | 15.38M |
| June 30, 2022 | 14.16M |
| March 31, 2022 | 38.08M |
| December 31, 2021 | 27.99M |
| September 30, 2021 | 9.21M |
| June 30, 2021 | 16.95M |
| March 31, 2021 | 15.71M |
| December 31, 2020 | 85.80M |
| September 30, 2020 | 18.19M |
| June 30, 2020 | 15.02M |
| March 31, 2020 | 13.29M |
| December 31, 2019 | 44.86M |
| September 30, 2019 | 13.28M |
| June 30, 2019 | 15.54M |
| March 31, 2019 | 8.584M |
| December 31, 2018 | 13.42M |
| September 30, 2018 | 10.93M |
| June 30, 2018 | 9.287M |
| March 31, 2018 | 19.82M |
| December 31, 2017 | 39.45M |
| September 30, 2017 | 8.48M |
| Date | Value |
|---|---|
| June 30, 2017 | 39.02M |
| March 31, 2017 | 28.50M |
| September 30, 2016 | 7.66M |
| June 30, 2016 | 7.408M |
| March 31, 2016 | 19.71M |
| December 31, 2015 | 18.03M |
| September 30, 2015 | 14.85M |
| June 30, 2015 | 12.61M |
| March 31, 2015 | 11.43M |
| December 31, 2014 | 48.30M |
| September 30, 2014 | 13.20M |
| June 30, 2014 | 5.743M |
| March 31, 2014 | 6.875M |
| December 31, 2013 | 30.06M |
| September 30, 2013 | 17.22M |
| June 30, 2013 | 3.831M |
| March 31, 2013 | 25.00M |
| December 31, 2012 | 2.612M |
| September 30, 2012 | 4.091M |
| June 30, 2012 | 2.952M |
| March 31, 2012 | 3.252M |
| December 31, 2011 | 7.617M |
| September 30, 2011 | 2.536M |
| June 30, 2011 | 6.505M |
| March 31, 2011 | 5.211M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
9.21M
Minimum
Sep 2021
113.42M
Maximum
Sep 2023
35.06M
Average
17.57M
Median
Revenue (Quarterly) Benchmarks
| AbbVie Inc | 12.31B |
| Pfizer Inc | 14.88B |
| Johnson & Johnson | 21.38B |
| Merck & Co Inc | 15.78B |
| Cerevel Therapeutics Holdings Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 30.75M |
| Total Expenses (Quarterly) | 87.47M |
| EPS Diluted (Quarterly) | 0.10 |
| Gross Profit Margin (Quarterly) | 98.10% |
| Profit Margin (Quarterly) | 27.11% |